Dave Edwards joins Blueberry Therapeutics
Blueberry Therapeutics are delighted to welcome Dave Edwards as Pharmaceutical Development Director, where he is responsible for CMC aspects of the manufacture of clinical supply materials through Phase II and III studies as well as subsequent commercialisation. Prior to this, [...]
Blueberry Therapeutics welcomes Office Assistant Jessica Harrison
We are delighted to welcome Jessica Harrison to the Blueberry team as an Office Assistant. Jess has vast experience in IT and holds a degree in Video Game Design. Outside of work, Jess likes to create concept art, pet [...]
Diane Lee joins the Blueberry team
We are delighted to welcome Diane Lee to the Blueberry Clinical Team. Diane has over 15 years’ experience in clinical research in different settings; Clinical Research Organisations, pharmaceutical companies and academic research. She has a science background with a BSc [...]
Anita Murray joins the Blueberry team as a Regulatory Affairs Director
Blueberry Therapeutics would like to extend a warm welcome to our newly appointed Regulatory Affairs Director, Anita Murray. Anita has an extensive background in both pharma and academia and brings with her many years of experience in Regulatory Compliance, [...]
CEO Dr. John Ridden talks Biotech Strategy & Nanomedicine
Blueberry Therapeutics’ CEO, Dr. John Ridden sat down with Pharmaphorum’s Dominic Tyer to talk strategy and bringing innovation to life through Blueberry Therapeutics' nanomedicine approach. Dr. Ridden also spoke about the concept of risk management in small biotech companies [...]
Blueberry Therapeutics welcomes Heather Davies!
Blueberry Therapeutics are delighted to welcome Heather Davies to the team as an Analytical Scientist. Heather is a biochemist by training and joins Blueberry after completing a post doc in France. She brings with her a wealth of experience from [...]
Blueberry Therapeutics wins Bionow’s Company of the Year Award
Alderley Park, UK, 4thDecember 2018– Blueberry Therapeutics won the coveted ‘Company of the Year’ award after another remarkable year of progress and innovation. 2018 has seen many great achievements for Blueberry Therapeutics including the completion of £10m Series B [...]
Noria joins Blueberry as a CRA
Blueberry Therapeutics are delighted to welcome Noria Mbuisa to the team! Noria joins us as a Clinical Research Associate, where she leads the review of study regulatory documents and data analysis. Noria has a Bachelor of Science Hons degree [...]
Blueberry Therapeutics welcomes Christian Little to the team
Blueberry Therapeutics would like to extend a warm welcome to Christian, who joins us with a wealth of experience as a Senior Clinical Project Manager. Christian has over 15 years’ experience in the pharmaceutical industry; three years in pipeline drug [...]
CEO to attend the Dermatology Drug Development Summit in Boston
Blueberry CEO, John Ridden, will be attending the 2nd Dermatology Drug Development Summit in Boston, 27-29th November 2018. The event is a unique industry-led conference focusing on innovating & accelerating the development amd commercialisation of dermatological medicines.
Blueberry Therapeutics Announce Positive Results from a Phase I/II Clinical Trial
Alderley Park, UK, 21stNovember 2018– Blueberry Therapeutics Limited (“Blueberry Therapeutics”), a modern drug discovery and development company committed to the development of innovative new therapies for the treatment of common and difficult to treat dermatological disorders, today announces that BB2603 [...]
CSO David Cook presents at ELRIG Drug Discovery Conference
David Cook presented at the recent ELRIG (European Laboratory Research and Innovation group) Drug Discovery Conference. David was invited to present in a workshop called “Build Biotech Success: A practical case study with CROs at Alderley Park”. The session focused [...]
Blueberry Therapeutics Limited closes £10m funding to support development of nanomedicines portfolio
Alderley Park, UK, 14 August 2018– Blueberry Therapeutics Limited, (“Blueberry Therapeutics”) a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections, today announces that it has successfully completed its £10m [...]
CEO attending BIO International, Boston
John Ridden, Blueberry CEO will be attending BIO International convention in Boston, 4th-7th June. 2018 is the 25th year for the BIO Convention, and attracts more than 16,000 biotechnology and pharma leaders who come together for one week of [...]
Blueberry CEO, CSO and FD to attend BioTrinity London 23-25 April
John Ridden, David Cook and Mark Hollingworth will be attending BioTrinity London 23-25 April. BioTrinity is Europe’s leading biopartnering and investment conference, and is in its 12thconsecutive year. The theme for 2018 is “Next Generation Healthcare”. We look forward to [...]
CSO David Cook presents at the OBN BioTuesday Seminar at Oxford’s Saïd Business School
David presented at a recent Oxford Bio Network (OBN) BioTuesday Seminar, "De-risking the Valley of Death – How R&D Companies can access the Knowledge Network to Maximise Success” as part of a delegation from the BioHub at Alderley Park. [...]
Blueberry CEO to attend the J.P. Morgan Annual Healthcare Conference
8th -11th of January 2018: CEO Dr. John Ridden has been invited to attend the J.P. Morgan 36th Annual Healthcare Conference in San Francisco, California. John will be presenting Blueberry to a number of prospective investors at this conference. [...]
Blueberry CSO presents at the Royal Society “Creating Connections” conference
Blueberry Therapeutics CSO David Cook presents at the first Royal Society Creating Connections conference, Research, industry and infrastructure in the North West, at Manchester's Museum of Science and Industry. David was invited to speak at this exciting event, which brought together academics, industry [...]
CEO presents to Chinese investors and companies
John Ridden, CEO of Blueberry Therapeutics, recently presented at the UK-China Life Science Event run by the DIT (Department for International Trade). The event was hosted by Lancaster University and is an opportunity for Life Science companies in the [...]
Blueberry to progress Nanomedicine platform to include novel Acne therapy
Blueberry Therapeutics Ltd is pleased to announce that it has taken a significant step forward in the development of new Acne treatments by gaining support from Innovate UK to co-fund critical research of this exciting programme. Principal Scientist Christine [...]
CEO John Ridden presents at Biofocus 2017
Blueberry Therapeutics CEO John Ridden presented at the Biofocus 2017 event at the Centre for Life in Newcastle upon Tyne as part of the Industry Showcase session. The Biofocus event is an annual event bringing together industry academia and experts [...]
Blueberry scientists attend “Kinetics, Binding and Biophysics in Drug Discovery” workshop
Blueberry Scientists Sarah Main and Julie Cook, attended the “Kinetics, Binding and Biophysics in Drug Discovery” workshop at The Mechanics Centre, Manchester on 27th June 2017. Attending the workshop will assist in current and future assay development in our antibiotic resistance [...]
Blueberry CSO attends the Mediscience Awards dinner
CSO David Cook attended the European Mediscience Awards Dinner in London as a guest of Zeus Capital. The Mediscience Awards recognize excellence in the Life Science sector and are held annually.
David Cook presents at ELRIG
CSO David Cook presented at the recent ELRIG (European Laboratory Research & Innovation Group) held at Alderley Park. David presented as part of a diverse evening of seminars on the topic “Novel Approaches to Meeting the Challenges of Antimicrobial Drug [...]
Blueberry Therapeutics commence Phase I/II clinical trial of lead product BB2603
Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals. The trial, which is a safety [...]